Aaron Miller
Hematology & Oncology · la Jolla, CANPI 1104127679
Payments from drug & device makers
What this record shows
This record is dominated by charitable contributions: $500 of the $641 with a category attached, or 78.1%. AstraZeneca accounts for 78.1% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $500 and has fallen 95.9% since, to $20 in 2023. That places this record below the midpoint for hematology & oncology clinicians in CA, where the typical reported total is $3,371.
Across 4 payments — averaging $160.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$500
- Merck$101
- United Therapeutics Corporation$20
- Eisai Inc.$20
Across 43 payments — averaging $11,759 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$425K
- Novartis$51K
- Incyte Corporation$30K
What the payments were for
- Food & beverage$14122%
- Charitable contribution$50078%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 1 | $500 |
| Merck | 1 | $101 |
| United Therapeutics Corporation | 1 | $20 |
| Eisai Inc. | 1 | $20 |
How this compares
$641 in reported general payments places this provider in the 25th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 22 | $44,412 |
| EliquisApixaban | 43 | $24,991 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 26 | $660 |
| Prochlorperazine Maleate | 55 | $505 |
| Oxycodone Hcl | 26 | $300 |
| Ondansetron Hcl | 46 | $298 |
| LoperamideLoperamide Hcl | 34 | $246 |
| Potassium Chloride | 13 | $199 |
| Doxycycline Hyclate | 13 | $176 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in la Jolla
- Alan Savenla Jolla$323K
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.